logo
Bill Clinton Writes Emotional Letter to 8-Year-Old Boy Waiting for Heart Transplant: ‘I Know How Scary It Can Be'

Bill Clinton Writes Emotional Letter to 8-Year-Old Boy Waiting for Heart Transplant: ‘I Know How Scary It Can Be'

Yahoo01-06-2025
Dáithí Mac Gabhann, 8, received an 'emotional' letter from Bill Clinton that left his "jaw on the floor," according to his dad
'As someone who's had heart surgery myself, I know how scary it can be, and I'm so impressed by the bravery you've shown throughout your life," the former president wrote to the boy
Clinton, 78, underwent quadruple bypass surgery in 2004Bill Clinton showed his support for a boy waiting for a heart transplant.
Dáithí Mac Gabhann, an 8-year-old who has been waiting for a heart transplant in Ireland since 2018, received a letter from the former president, 78. The Donate4Dáithí fundraising campaign shared the letter, which was dated and signed on May 13, in an Instagram post on May 30.
"It's not every day a letter comes through [the] door in Ballymurphy from a former US President… 🩷 #OrganDonation," the caption of the post said.
The letterhead read, "William Jefferson Clinton," and the note was typed, although Clinton appeared to have signed his name in ink at the bottom — with a handwritten message that read, "Keep going!"
"Dear Dáithí," the letter read. "Your dad wrote to tell me about your recent visit to City Hall to see your name listed among the Freemen of Belfast. I'm so proud to share that honor with someone as amazing as you."
Per the Belfast City Council, Dáithí received the Freedom of the City honor in 2023 after his successful campaign to change Northern Ireland's organ donation laws. Meanwhile, Clinton earned the civic honor in 2018 for his peace-building efforts in the country. BBC reported at the time that Dáithí was the youngest person to receive the honor at just 6 years old.
"As someone who's had heart surgery myself, I know how scary it can be, and I'm so impressed by the bravery you've shown throughout your life," the letter continued, in reference to Clinton's quadruple bypass in 2004. "I'm also deeply inspired by the way you and your family have worked hard to make positive change across Northern Ireland. Our world would be better if there were more people like you!"
"I hope I'll have the chance to meet you and your family next time I'm in Belfast. Until then, keep up your great work, and know that you have a big fan pulling for you in New York," the note concluded.
Dáithí's father, Máirtín Mac Gabhann, told BBC that the letter "stopped me in my tracks ... the fact someone like President Clinton took the time to write this letter is amazing."
The proud dad said his son had his "jaw on the floor" when he received the letter. "He knew this was big ... he couldn't believe it ... he was even getting a bit emotional about it all," Máirtín said.
The letter, according to the father, has given the family momentum as they near their seventh year of waiting for a transplant. "It gave us a much needed boost," he told the British broadcaster. "Dáithí is stable now but this letter has saved the day for us ... as he had been at hospital."
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human-interest stories.
Dáithí reached the anniversary date on Sunday, June 1, per Donate4Dáithí. The campaign shared a happy photo of the young boy at a sports stadium while decked out in Liverpool F.C. gear on Instagram to mark the occasion.
"7 years on the waiting list for a heart transplant today. Still smiling. Still fighting. Let's see how far this can go for #OrganDonation. Help us keep the message alive," the caption read.
Per the Department of Health in Northern Ireland, Dáithi's Law came into effect on June 1, 2023.
The law means that adults in Northern Ireland are considered potential organ donors unless they actively opt out or are part of an excluded group.
Read the original article on People
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Market to Reach $34.5 Billion by 2030 - Rise of mRNA-based Protein Replacement Therapies Strengthens Demand
Market to Reach $34.5 Billion by 2030 - Rise of mRNA-based Protein Replacement Therapies Strengthens Demand

Yahoo

time2 hours ago

  • Yahoo

Market to Reach $34.5 Billion by 2030 - Rise of mRNA-based Protein Replacement Therapies Strengthens Demand

The mRNA Therapeutics market is expanding due to advancements in drug development, personalized medicine, and delivery technologies. Opportunities arise from the technology's success in vaccines and potential in treating diverse diseases like cancer and genetic disorders. Challenges include regulatory and manufacturing hurdles but increased investment and innovation drive growth. mRNA Therapeutics Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics - Global Strategic Business Report" report has been added to global market for mRNA Therapeutics was estimated at US$13.3 Billion in 2024 and is projected to reach US$34.5 Billion by 2030, growing at a CAGR of 17.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The rise of mRNA therapeutics has fundamentally changed the landscape of drug development, offering a powerful platform for treating a wide range of diseases, from infectious diseases and cancer to genetic disorders and rare conditions. Unlike traditional biologics, which require complex production processes and cell culture systems, mRNA-based therapies leverage synthetic messenger RNA to instruct cells to produce therapeutic proteins directly within the body. This approach significantly accelerates drug development timelines and enhances precision in targeting disease pathways. The groundbreaking success of mRNA COVID-19 vaccines demonstrated the speed and flexibility of this technology, leading to a surge in research efforts aimed at expanding mRNA applications beyond vaccines. The ability to encode virtually any protein into an mRNA sequence has positioned this technology as a promising tool for personalized medicine, where treatments can be tailored to an individual's genetic profile. Additionally, advancements in lipid nanoparticle (LNP) delivery systems have improved the stability and targeted delivery of mRNA therapeutics, addressing previous challenges related to degradation and immunogenicity. As pharmaceutical companies and research institutions continue to invest in mRNA-based solutions, the potential for treating conditions such as autoimmune diseases, cardiovascular disorders, and neurodegenerative conditions is rapidly expanding, making mRNA therapeutics one of the most dynamic areas in modern biotechnology. What Are the Key Growth Drivers Propelling the mRNA Therapeutics Market?The growth in the mRNA therapeutics market is driven by several factors, including increasing investments in biotechnology research, expanding applications beyond vaccines, and technological advancements in mRNA delivery systems. The success of mRNA-based COVID-19 vaccines has significantly boosted funding for mRNA research, leading to an influx of clinical trials investigating mRNA therapies for cancer, metabolic diseases, and infectious diseases such as influenza, HIV, and Zika virus. The rise of personalized medicine has also accelerated interest in mRNA-based cancer vaccines, where patients receive customized treatments targeting specific tumor antigens. Additionally, the growing adoption of AI-driven drug discovery is streamlining mRNA sequence design, optimizing formulations, and reducing development timelines. The increasing demand for decentralized vaccine production and regional manufacturing hubs has spurred investments in mRNA production facilities, further supporting market expansion. The continued refinement of lipid nanoparticles and alternative delivery systems has enhanced the efficacy and safety of mRNA drugs, driving broader clinical adoption. Furthermore, government initiatives focused on pandemic preparedness and biopharmaceutical innovation are providing funding and regulatory support for mRNA therapeutics. As new indications emerge and manufacturing capabilities improve, the mRNA therapeutics market is poised for sustained growth, revolutionizing the treatment landscape for numerous diseases and positioning mRNA technology as a cornerstone of next-generation medicine. What Technological Advancements Are Enhancing the Efficacy and Delivery of mRNA Drugs?The rapid evolution of mRNA therapeutics is largely driven by advancements in formulation, delivery technologies, and sequence optimization. One of the most significant breakthroughs has been the development of chemically modified nucleotides, such as N1-methylpseudouridine, which enhance mRNA stability and reduce unwanted immune responses. Improved in vitro transcription (IVT) processes have increased mRNA yield and purity, reducing the presence of double-stranded RNA contaminants that can trigger inflammatory responses. The refinement of lipid nanoparticle (LNP) carriers has also played a crucial role in improving mRNA delivery, ensuring that the therapeutic payload reaches target tissues with high efficiency while minimizing off-target effects. Researchers are now exploring next-generation delivery systems, including polymer-based nanoparticles, exosome-derived vesicles, and peptide-based formulations, to further enhance tissue specificity and prolonged therapeutic effects. Additionally, the emergence of self-amplifying mRNA (saRNA) has opened new possibilities for lower-dose, longer-lasting treatments by enabling the production of therapeutic proteins at reduced mRNA concentrations. As artificial intelligence (AI) and machine learning are integrated into drug discovery, predictive modeling is being used to optimize mRNA sequences and delivery strategies, accelerating the development of novel mRNA-based therapies. These technological advancements are expected to expand the scope of mRNA therapeutics, unlocking new treatment paradigms across multiple disease Are Regulatory and Manufacturing Challenges Impacting the mRNA Therapeutics Market?Despite the immense potential of mRNA therapeutics, the industry faces regulatory and manufacturing challenges that must be addressed to enable widespread adoption. The highly specialized nature of mRNA production requires stringent quality control measures, particularly in raw material sourcing, in vitro transcription, and purification processes. Regulatory agencies such as the FDA and EMA have introduced new guidelines for mRNA therapeutics, focusing on product stability, immunogenicity, and manufacturing scalability. The need for Good Manufacturing Practice (GMP)-compliant production facilities has increased demand for contract development and manufacturing organizations (CDMOs) that specialize in mRNA drug production. However, the global supply chain for key components such as nucleotides, capping reagents, and lipid carriers remains vulnerable to disruptions, posing risks to large-scale manufacturing. Additionally, regulatory frameworks are still evolving for personalized mRNA therapies, such as cancer vaccines, which require customized formulations for individual patients. Another key challenge is the cost of production, as mRNA-based drugs often require cold-chain storage and sophisticated logistics for global distribution. Addressing these challenges will require continued collaboration between biotech companies, regulatory agencies, and manufacturing partners to ensure that mRNA therapeutics can be developed and distributed efficiently and safely on a global scale. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abogen Biosciences, Alnylam Pharmaceuticals, Anima Biotech, Arcturus Therapeutics Holdings Inc., BioNTech SE and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Prophylactic Products segment, which is expected to reach US$25.6 Billion by 2030 with a CAGR of a 18.3%. The Therapeutic Products segment is also set to grow at 14.2% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $3.6 Billion in 2024, and China, forecasted to grow at an impressive 22.8% CAGR to reach $7.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Scope of Study: Type (Prophylactic Products, Therapeutic Products) Application (Infectious Diseases Application, Oncology Application, Rare Genetic Diseases Application, Respiratory Diseases Application, Other Applications) End-Use (Hospitals & Clinics End-Use, Research Organizations End-Use, Other End-Uses) Key Attributes: Report Attribute Details No. of Pages 282 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $13.3 Billion Forecasted Market Value (USD) by 2030 $34.5 Billion Compound Annual Growth Rate 17.1% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns mRNA Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Increasing Investment in mRNA Technology for Therapeutic Development Drives Market Growth Surge in Global Demand for mRNA-Based Vaccines Expands Market Opportunity for mRNA Therapeutics Accelerated Research and Development in mRNA-Based Cancer Therapies Expands Market Horizons Regulatory Support and Fast-Track Approvals for mRNA Therapies Strengthen Market Confidence and Adoption Technological Advancements in mRNA Delivery Systems Propel Growth in Therapeutic Applications Rising Consumer Demand for Personalized Medicine Drives Adoption of mRNA Therapeutics in Tailored Treatment Plans The Emergence of mRNA-based Infectious Disease Treatments Spells Long-term Growth for the Therapeutics Market Increasing Use of mRNA Vaccines in Global Immunization Campaigns Accelerates Market Adoption The Shift Toward Preventive Healthcare and Proactive Disease Management Boosts Demand for mRNA Therapeutics Growing Integration of mRNA Technology into Cancer Immunotherapies Expands Market Opportunity Increasing Collaborations Between Biopharma Companies and Research Institutions Fuel mRNA Therapeutics Innovation The Global COVID-19 Pandemic Drives Significant Investment and Infrastructure Development for mRNA Therapeutics Expansion of Clinical Trials for mRNA Therapeutics in Rare and Genetic Diseases Spurs Market Potential Rising Focus on the Safety and Efficacy of mRNA-based Therapies Strengthens Consumer Confidence and Adoption The Growing Role of Artificial Intelligence and Machine Learning in mRNA Therapeutics Development Drives Innovation Expansion of Manufacturing Capabilities for mRNA-based Drugs Increases Market Accessibility and Scalability Increasing Global Health Initiatives and Public-Private Partnerships Accelerates Demand for mRNA Therapeutics The Rise of mRNA-based Protein Replacement Therapies Strengthens Market Demand for mRNA in Genetic Disorders Regulatory and Ethical Issues Surrounding mRNA Technology Drive Innovation in Safety Protocols and Guidelines Increasing Interest in mRNA as a Platform for Targeted Therapies Expands Addressable Market Opportunity for Therapeutic Products FOCUS ON SELECT PLAYERS | Some of the 48 Companies Featured in This Report Abogen Biosciences Alnylam Pharmaceuticals Anima Biotech Arcturus Therapeutics Holdings Inc. BioNTech SE Comanche Biopharma CureVac N.V. eTheRNA Immunotherapies NV Ethris GmbH EXACIS Biotherapeutics Gritstone bio, Inc. HC Bioscience Inflammatix, Inc. Ionis Pharmaceuticals Moderna, Inc. Nutcracker Therapeutics Orna Therapeutics ReCode Therapeutics Strand Therapeutics Translate Bio (Acquired by Sanofi) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment mRNA Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Reeves concedes Government has ‘more to do' as unemployment at four-year high
Reeves concedes Government has ‘more to do' as unemployment at four-year high

Yahoo

time2 hours ago

  • Yahoo

Reeves concedes Government has ‘more to do' as unemployment at four-year high

Rachel Reeves conceded the Government had 'more to do' but defended her stewardship of the economy as figures showed the UK's unemployment rate stuck at a four-year high. The Chancellor insisted Labour had been 'creating more jobs' since entering office despite vacancies declining over the last quarter, with experts warning of a further 'cooling in the labour market'. Speaking to reporters on a visit to Belfast on Tuesday, Ms Reeves said the Government had returned stability to the economy but that there was 'absolutely' more progress to be made. 'There is more to do, but in the first year, we've managed to return stability to the economy, we're growing the economy and reducing costs, particularly mortgage costs for hard-pressed families,' she said. The Office for National Statistics (ONS) earlier released figures showing the rate of UK unemployment struck 4.7% in the three months to June. It was the same as the previous three-month period, which had been the highest level since June 2021. Meanwhile, average earnings growth, excluding bonuses, remained at 5% for the period to June. UK vacancies tumbled by 44,000 over the three months to July to 718,000 – the lowest number of job openings since April 2021. Ms Reeves acknowledged there had been a decline in the quarter but said there was 'really positive news' in the figures, with some 384,000 more jobs in the economy than there were just over a year ago. 'The most important figure today is that there are 384,000 more people in work than when I became Chancellor,' she said. 'Everybody who can work should be in work, and as a government, we're committed to helping more people back to work. There are huge opportunities in our economy.' The signs of further pressure in the labour market alongside recent weak economic growth pose a challenge for the Government and policymakers at the Bank of England. Last week, the Bank of England indicated that unemployment was likely to rise further later this year as it chose to cut interest rates again to 4%. The latest labour market statistics from the ONS were in line with predictions from economists. The data showed that the number of payrolled employees fell by 66,000 for the quarter to June, with an estimated 26,000 drop between May and June. It came as figures also revealed that recent weakness in the UK hiring market continued further, with vacancies dropping to a four-year low. Vacancy numbers fell 5.8% over the quarter to July, with a particularly sharp drop in the arts, entertainment and recreation sectors. Meanwhile, wage growth remained at 5% for the three months to June, but was only 1.5% once inflation is taken into account, thanks to an uptick in the cost of living in recent months. ONS director of economic statistics Liz McKeown said: 'Taken together, these latest figures point to a continued cooling of the labour market. 'The number of employees on payroll has now fallen in 10 of the last 12 months, with these falls concentrated in hospitality and retail. 'Job vacancies, likewise, have continued to fall, also driven by fewer opportunities in these industries.' James Smith, economist at ING, said: 'The UK jobs market is undoubtedly cooling, though a more modest fall in payroll employment suggests that the worst may be behind us, following big tax and living wage hikes. 'Better news on wage growth suggests the Bank can still afford to cut rates in November, though after last week's hawkish meeting, this call has become less clear-cut.' The figures come amid warnings from economists that the Chancellor will have to hike taxes in the autumn budget to plug a black hole of up to £51 billion in the public finances. The National Institute of Economic and Social Research (Niesr) earlier this month said weaker-than-expected recent economic activity, U-turns on welfare cuts and forecast-beating borrowing mean Ms Reeves is on track to miss one of her fiscal rules by £41.2 billion in 2029-30. Including the need to rebuild the fiscal buffer of just under £10 billion that has been wiped out, she will have to find more than £51 billion, according to the leading think tank. Ms Reeves has refused to rule out tax rises at the budget since Labour MPs forced ministers to make concessions on welfare reforms, which the Government had hoped would save up to £5 billion a year.

Reeves concedes Government has ‘more to do' as unemployment at four-year high
Reeves concedes Government has ‘more to do' as unemployment at four-year high

Yahoo

time4 hours ago

  • Yahoo

Reeves concedes Government has ‘more to do' as unemployment at four-year high

Rachel Reeves conceded the Government had 'more to do' but defended her stewardship of the economy as figures showed the UK's unemployment rate stuck at a four-year high. The Chancellor insisted Labour had been 'creating more jobs' since entering office despite vacancies declining over the last quarter, with experts warning of a further 'cooling in the labour market'. Speaking to reporters on a visit to Belfast on Tuesday, Ms Reeves said the Government had returned stability to the economy but that there was 'absolutely' more progress to be made. 'There is more to do, but in the first year, we've managed to return stability to the economy, we're growing the economy and reducing costs, particularly mortgage costs for hard-pressed families,' she said. The Office for National Statistics (ONS) earlier released figures showing the rate of UK unemployment struck 4.7% in the three months to June. It was the same as the previous three-month period, which had been the highest level since June 2021. Meanwhile, average earnings growth, excluding bonuses, remained at 5% for the period to June. UK vacancies tumbled by 44,000 over the three months to July to 718,000 – the lowest number of job openings since April 2021. Ms Reeves acknowledged there had been a decline in the quarter but said there was 'really positive news' in the figures, with some 384,000 more jobs in the economy than there were just over a year ago. 'The most important figure today is that there are 384,000 more people in work than when I became Chancellor,' she said. 'Everybody who can work should be in work, and as a government, we're committed to helping more people back to work. There are huge opportunities in our economy.' The signs of further pressure in the labour market alongside recent weak economic growth pose a challenge for the Government and policymakers at the Bank of England. Last week, the Bank of England indicated that unemployment was likely to rise further later this year as it chose to cut interest rates again to 4%. The latest labour market statistics from the ONS were in line with predictions from economists. The data showed that the number of payrolled employees fell by 66,000 for the quarter to June, with an estimated 26,000 drop between May and June. It came as figures also revealed that recent weakness in the UK hiring market continued further, with vacancies dropping to a four-year low. Vacancy numbers fell 5.8% over the quarter to July, with a particularly sharp drop in the arts, entertainment and recreation sectors. Meanwhile, wage growth remained at 5% for the three months to June, but was only 1.5% once inflation is taken into account, thanks to an uptick in the cost of living in recent months. ONS director of economic statistics Liz McKeown said: 'Taken together, these latest figures point to a continued cooling of the labour market. 'The number of employees on payroll has now fallen in 10 of the last 12 months, with these falls concentrated in hospitality and retail. 'Job vacancies, likewise, have continued to fall, also driven by fewer opportunities in these industries.' James Smith, economist at ING, said: 'The UK jobs market is undoubtedly cooling, though a more modest fall in payroll employment suggests that the worst may be behind us, following big tax and living wage hikes. 'Better news on wage growth suggests the Bank can still afford to cut rates in November, though after last week's hawkish meeting, this call has become less clear-cut.' The figures come amid warnings from economists that the Chancellor will have to hike taxes in the autumn budget to plug a black hole of up to £51 billion in the public finances. The National Institute of Economic and Social Research (Niesr) earlier this month said weaker-than-expected recent economic activity, U-turns on welfare cuts and forecast-beating borrowing mean Ms Reeves is on track to miss one of her fiscal rules by £41.2 billion in 2029-30. Including the need to rebuild the fiscal buffer of just under £10 billion that has been wiped out, she will have to find more than £51 billion, according to the leading think tank. Ms Reeves has refused to rule out tax rises at the budget since Labour MPs forced ministers to make concessions on welfare reforms, which the Government had hoped would save up to £5 billion a year.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store